Study Suggests CLR01 May Improve Symptoms of Early Parkinsonís

Share

(July 7, 2017) – Treatment with a drug called CLR01 improved balance and movement coordination in mice with early stage Parkinson’s disease, according to results of a new preclinical study. Researchers said CLR01 acts by decreasing the amount of unstable alpha-synuclein, one of the two forms of the protein existing in the brain, and the one that is believed to be associated with the development of Parkinson’s disease. Read more

Earlier research by Gal Bitan at UCLA that was in part funded by The Parkinson Alliance using funds raised by the Parkinson’s Unity Walk, led to the development of CLR01.

Click for a printer friendly version

Back to top